ACE-011
by Alyssa Liguori| Brand Name: | |
| Generic Name: | |
| Code Name: | ACE-011 |
| Company: | Celgene and Acceleron Pharma |
| FDA Clinical Phase: | 2 |
Description:
ACE-011 is a human fusion protein from the combination of Activin Receptor Type IIA and an antibody molecule. It is called a fusion protein because scientists have joined two different genes, each of which typically code for separate proteins. By fusing the genes, a new, unique protein is created with certain functions from both of the original proteins. This fusion protein, ACE-011, inhibits bone loss and promotes bone formation.
Clinical Trials:
There is one ongoing clinical trial studying ACE-011 for the treatment of multiple myeloma patients with bone lesions, but it is not currently recruiting.
Web site for ACE-011: http://www.acceleronpharma.com.
Updated December 26, 2009
Related Articles:
- Anti-DKK1 Antibody As New Treatment For Myeloma Bone Disease
- Immune System Cells Protect Myeloma Cancer Cells, Study Finds
- Novel Therapies For Myeloma Bone Disease
- Bone Formation And Degradation Proteins May Predict Progression Of Multiple Myeloma And Myeloma-Related Bone Disease
- Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
Leave a comment